EP1697322A1 - Derives de tetrahydrocarbazole et de cyclopentanoindole substitues - Google Patents

Derives de tetrahydrocarbazole et de cyclopentanoindole substitues

Info

Publication number
EP1697322A1
EP1697322A1 EP04802298A EP04802298A EP1697322A1 EP 1697322 A1 EP1697322 A1 EP 1697322A1 EP 04802298 A EP04802298 A EP 04802298A EP 04802298 A EP04802298 A EP 04802298A EP 1697322 A1 EP1697322 A1 EP 1697322A1
Authority
EP
European Patent Office
Prior art keywords
compound
fluoro
carbazol
methylsulfonyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04802298A
Other languages
German (de)
English (en)
Other versions
EP1697322A4 (fr
Inventor
Christian Beaulieu
Daniel Guay
Zhaoyin Wang
Robert Zamboni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1697322(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of EP1697322A1 publication Critical patent/EP1697322A1/fr
Publication of EP1697322A4 publication Critical patent/EP1697322A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Definitions

  • the present invention relates to compounds and methods for treating prostaglandin mediated diseases, and certain pharmaceutical compositions thereof. More particularly, the compounds ofthe invention are structurally different from steroids, antihistamines or adrenergic agonists, and are antagonists of the nasal and pulmonary congestion effects of D-type prostaglandins.
  • Two review articles describe the characterization and therapeutic relevance of the prostanoid receptors as well as the most commonly used selective agonists and antagonists: Eicosanoids: From Biotechnology to Therapeutic Applications, Folco, Samuelsson, Maclouf, and Velo eds, Plenum. Press, New York, 1996, chap. 14, 137-154 and Journal of Lipid Mediators and Cell Signalling, 1996, 14, 83-87.
  • PGD2 is considered to be an important mediator in various allergic diseases such allergic rhinitis, atopic asthma, allergic conjunctivitis and atopic dermatitis. More recently, an article by Matsuoka et al. in Science (2000), 287:2013-7, describes PGD2 as being a key mediator in allergic asthma. In addition, patents such as US 4,808,608 refer to prostaglandin antagonists as useful in the treatment of allergic diseases, and explicitly allergic asthma. PGD2 antagonists are described in, for example, European Patent Application 837,052 and PCT Application W098/25919, as well as W099/62555.
  • the present invention provides novel compounds which are prostaglandin receptor antagonists; more particularly, they are prostaglandin D2 receptor (DP receptor) antagonists.
  • Compounds of the present invention are useful for the treatment of various prostaglandin-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of prostaglandin-mediated diseases using the novel compounds described herein, as well as pharmaceutical compositions containing them.
  • n 0 or 1;
  • Rl is hydrogen or halogen;
  • R is halogen, cyano, C ⁇ _3alkylsulfonyl or trifluoromethyl;
  • R is C ⁇ -3alkyl optionally substituted with 1-5 halogen atoms; and
  • R a and R b are each hydrogen or one is hydrogen and the other is hydroxy, or both together represent oxo; with the proviso that when Rl is hydrogen, R is not 4-chloro.
  • R a and R b are each hydrogen.
  • Rl is hydrogen and R is trifluoromethyl.
  • a third embodiment of formula I are compounds wherein R is methyl.
  • Rl and R are independently a halogen atom.
  • n is 1.
  • R3 is CH3, and R a and R4b are each hydrogen.
  • R a and R4b are each hydrogen.
  • n 1, Rl is hydrogen, R3 is methyl, R a and R b are each hydrogen, and R2 is 4-cyano, 4-methanesulfonyl or 4-trifluoromethyl.
  • the present invention further provides a compound selected from: ((lR)-6-fluoro-8-(methylsulfonyl)-9- ⁇ (lS)-l-[4-(trifluoromethyl) ⁇ henyl]ethyl ⁇ -2,3,4,9-tetrahydro-lH- carbazol-l-yl)acetic acid;
  • compositions comprising a compound of formula I, and a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions further comprises a second active ingredient selected from an antihistamine, a leukotriene antagonist, leukotriene biosynthesis inhibitor, prostaglandin receptor antagonists or biosynthesis inhibitors, corticosteroids, cytokine modulators, anti-
  • a method for the treatment or prevention of prostaglandin D2 mediated diseases which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound of formula I.
  • D2 mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula I in an amount which is effective for treating or preventing a prostaglandin D2 mediated disease, wherein the prostaglandin mediated disease is nasal congestion, rhinitis including seasonal allergic rhinitis and perennial allergic rhinitis, and asthma including allergic asthma.
  • a method for the treatment of nasal congestion in a patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of formula I.
  • a method for the treatment of asthma, including allergic asthma in a patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of formula I.
  • the present invention is a method for the treatment of allergic rhinitis (seasonal and perennial) in a patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of formula I.
  • Another aspect of the present invention provides a method for preventing or reducing niacin-induced flushing in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula I.
  • Another aspect of the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of conditions for which the administration of a DP receptor antagonist is indicated.
  • halogen includes fluorine, chlorine, bromine and iodine.
  • alkyl includes linear and branched carbon chains having the indicated range of carbon atoms. The numbering of the core tricyclic ring systems of formula I is as shown below:
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases.
  • Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethyl- aminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • basic ion exchange resins such
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.
  • Compounds of formula I are antagonists of prostaglandin D2.
  • the ability of compounds of formula I to interact with prostaglandin D2 receptor makes them useful for preventing or reversing undesirable symptoms caused by prostaglandins in a mammalian, especially human subject.
  • the antagonism of the actions of prostaglandin D2 indicates that the compounds and pharmaceutical compositions thereof are useful to treat, prevent, or ameliorate in mammals and especially in humans: respiratory conditions, allergic conditions, pain, inflammatory conditions, mucus secretion disorders, bone disorders, sleep disorders, fertility disorders, blood coagulation disorders, trouble of the vision as well as immune and autoimmune diseases.
  • such a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer.
  • Compounds of formula I may also be of use in the treatment and/or prevention prostaglandin D2 mediated proliferation disorders such as may occur in diabetic retinopathy and tumor angiogenesis.
  • Compounds of formula I may also inhibit prostanoid-induced smooth muscle contraction by antagonizing contractile prostanoids or mimicking relaxing prostanoids and hence may be used in the treatment of dysmenorrhea, premature labor and eosinophil related disorders. Accordingly, another aspect of the invention provides a method of treating or preventing a prostaglandin D2 mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula I in an amount which is effective for treating or preventing said prostaglandin D2 mediated disease.
  • Prostaglandin D2 mediated diseases include, but are not limited to, allergic rhinitis, nasal congestion, rhinorrhea, perennial rhinitis, nasal inflammation, asthma including allergic asthma, chronic obstructive pulmonary diseases and other forms of lung inflammation; pulmonary hypotension; sleep disorders and sleep-wake cycle disorders; prostanoid-induced smooth muscle contraction associated with dysmenorrhea and premature labor; eosinophil related disorders; thrombosis; glaucoma and vision disorders; occlusive vascular diseases, such as for example atherosclerosis; congestive heart failure; diseases or conditions requiring a treatment of anti-coagulation such as post-injury or post surgery treatment; rheumatoid arthritis and other inflammatory diseases; gangrene; Raynaud's disease; mucus secretion disorders including cytoprotection; pain and migraine; diseases requiring control of bone formation and resorption such as for example osteoporosis; shock; thermal regulation including fever; rejection in organ transplant and by-
  • the disease to be treated is one mediated by prostaglandin D2 such as nasal congestion, allergic rhinitis, pulmonary congestion, and asthma including allergic asthma.
  • prostaglandin D2 such as nasal congestion, allergic rhinitis, pulmonary congestion, and asthma including allergic asthma.
  • compounds of formula I are useful for alleviating flushing caused by niacin or nicotinic acid (pyridine-3-carboxylic acid), a drug commonly known for its effect in elevating serum levels of high density lipoproteins (HDL).
  • niacin pyridine-3-carboxylic acid
  • HDL high density lipoproteins
  • Niacin is frequently associated with cutaneous vasodilation, sometimes called flushing. This side effect is caused by the nicotinic acid-induced release of prostaglandin D2 in the skin and is so severe that many patients discontinue nicotinic acid treatment.
  • the present invention provides for a method for preventing or reducing niacin-induced flushing in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of formula I.
  • niacin and the compound of formula I may be administered together in unit dosage form or in separate dosage forms, or the compounds may be administered sequentially.
  • the magnitude of prophylactic or therapeutic dose of a compound of formula I will, of course, vary with the nature and the severity of the condition to be treated and with the particular compound of formula I and its route of administration. It will also vary according to a variety of factors including the age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination and response ofthe individual patient. In general, the daily dose from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 10 mg per kg. On the other hand, it may be necessary to use dosages outside these limits in some cases.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration of humans may contain from 0.05 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 99.95 percent of the total composition.
  • Dosage unit forms will generally contain between from about 0.1 mg to about 0.4 g of an active ingredient, typically 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, or 400 mg.
  • compositions comprising a compound of formula I with a pharmaceutically acceptable carrier.
  • composition is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of Formula I, additional active ingredient(s), and pharmaceutically acceptable excipients.
  • compounds of formula I may be administered orally, by inhalation spray, topically, parenterally or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques.
  • warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc.
  • the compound of the invention is effective in the treatment of humans.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally- occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.
  • dispersing or wetting agents may be a naturally- occurring phosphatide, for example lecithin, or condensation products of an al
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation.
  • compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of an oil-in- water emulsion.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally- occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3- butane diol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used, hi addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Compounds of formula I may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • a suitable non- irritating excipient which is solid at ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.
  • compound of formula I may be co-administered with other therapeutic agents.
  • the present invention provides pharmaceutical compositions for treating prostaglandin D2 mediated diseases or conditions comprising a therapeutically effective amount of a compound of formula I and one or more other therapeutic agents.
  • Suitable therapeutic agents for combination therapy with a compound of formula I include: (1) a prostaglandin receptor antagonist; (2) a corticosteroid such as triamcinolone acetonide; (3) a ⁇ -agonist such as salmeterol, formoterol, terbutaline, metaproterenol, albuterol and the like; (4) a leukotriene modifier, such as a leukotriene antagonist or a lipooxygenase inhibitor such as montelukast, zafirlukast, pranlukast, or zileuton; (5) an antihistamine (histamine HI antagonist) such as bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripelennamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproh
  • Ariflo, roflumilast (13) antagonists of the chemokine receptors, especially CCR-1, CCR-2, and CCR-3; (14) cholesterol lowering agents such as HMG-CoA reductase inhibitors (lovastatin, simvastatin and pravastatin, fluvastatin, atorvastatin, and other statins), sequestrants (cholestyramine and colestipol), nicotinic acid, fenofibric acid derivatives (gemfibrozil, clofibrat, fenofibrate and benzafibrate), and probucol; (15) anti-diabetic agents such as insulin, sulfonylureas, biguanides (metformin), -glucosidase inhibitors (acarbose) and glitazones (troglitazone, pioglitazone, englitazone, rosiglitazone and the like); (16) preparation
  • the invention encompasses a method of treating prostaglandin D2 mediated diseases or conditions comprising: administering to a patient in need of such treatment a therapeutically effective amount of the compound of formula I, co-administered with one or more of such ingredients as listed immediately above.
  • the amounts of active ingredients may be those commonly used for each active ingredient when it is administered alone, or in some instances the combination of active ingredients may result in lower dosage for one or more of the active ingredients.
  • the present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of niacin and a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the present invention also provides for the use of a compound of formula I or a pharmaceutically acceptable salt thereof and niacin in the manufacture of a medicament for elevating serum high density lipoprotein while reducin niacin-induced flushing.
  • Scheme 1 depicts the preparation of intermediates of Formula IN from phenyl hydrazine II and cycloalkanone in (where R is ester group such as an alkyl group) under Fisher lhdole or similar conditions
  • Scheme 1 depicts the preparation of intermediates of Formula IN from phenyl hydrazine II and cycloalkanone in (where R is ester group such as an alkyl group) under Fisher lhdole or similar conditions
  • Scheme 2 depicts the preparation of compounds of Formula 111 from silyl enol ether Ilia or enamine nib.
  • Reaction of an appropriate electrophile such as Y-CH2CO2R (wherein Y represents a halogen or a leaving group) in the presence of a base such as an alkyl lithium or a Lewis acid such as silver trifluoroacetate with the silyl enol ether ITIa gives the cycloalkanone HI.
  • the compound of formula Dl may alternatively be prepared from the addition of Y-CH2CO2R on an appropriately substituted enamine IJJb under Stork Enamine or similar conditions.
  • Scheme 3 depicts the preparation of compounds of Formula I from the chiral bromoindole INa.
  • the racemic mixture of IN may be resolved using conventional techniques; for example by resolution of IN by chiral HPLC, by enantioselective enzymatic transformations using enzymes such as esterases, or by using optically active resolving agents.
  • Alkylation of INa with an electrophile such as the benzyl compound N in the presence of a base and in a suitable solvent such as DMF gives ⁇ -alkylated indole NIL
  • Coupling of Nil with a methanesulfinate such as sodium methanesulfinate in the presence of Cu(L) salts leads to compounds of formula I, following ester hydrolysis.
  • a suitable metallation agent such as ⁇ -BuLi
  • an electrophile such as methyl disulfide
  • the steps of alkylation of the bromoindole INa followed by sulfonylation may also be reversed; thus sulfonylation of the bromoindole INa provides the compound VI, which is alkylated using similar conditions as described before or by using Mitsunobu reaction conditions with benzyl alcohol N ⁇ i to provide compound of formula la following ester hydrolysis.
  • Scheme 4 depicts the preparation of compounds of Formula I from the chiral sulfone LXa.
  • the racemic sulfone LX is prepared from coupling of bromide IN with a methanesulfinate such as sodium methanesulfinate in the presence of Cu(I) salts, which is then resolved by chiral HPLC, enantioselective enzymatic hydrolysis or by chiral resolving agents to afford the chiral sulfone LXa.
  • Alkylation of LXa with an electrophile or by using Mitsunobu reaction condition as described in Scheme 3 provides compound of Formula la following ester hydrolysis.
  • Diastereoselective hydrolysis of X using LiOH at 0°C affords the compound of Formula la and the ester Xa as single diastereomers which are easily separable by conventional separation techniques.
  • the chiral sulfone LXb could also be prepared from la by hydrogenolysis reaction using palladium on charcoal in MeOH to afford the methyl ester LXb as depict in Scheme 6.
  • Compound lb may be prepared from LXa, by oxidation using a suitable oxidant such as DDQ in THF, followed by alkylation step and by hydrolysis as illustrated in Scheme 3.
  • Chiral alcohol N ⁇ i may be prepared from the corresponding ketone XII by enantioselective reduction with a number of chiral reducing agents such as the combination of BH 3 .SMe 2 with (Me)-CBS.
  • Scheme 8 chiral reduction
  • Compounds of Formula Ic and Id may be prepared by the sequence illustrated in Scheme 9.
  • Asymmetric dihydroxylation of XHI using condition such as Sharpless dihydroxylation afford the diol XTV which is selectively protected with a protective group such as TBDMS to afford XV.
  • Compound XVI is prepared by Mitsunobu reaction type between indole IX and alcohol XV and then deprotected with reagent such as TBAF.
  • Compound of Formula Ic is then obtained following the conversion of XVII to the corresponding mesylate and treatment of the latter with fluorinating agent such as NEt 3 .3HF and finally by ester hydrolysis.
  • Compound of Formula Id is prepared from XVII following oxidation, fluorination with reagent such as DAST and ester hydrolysis.
  • Compounds of Formula Ie may be may be prepared by the sequence illustrated in Scheme 10. Oxidation of XVII using for example Dess-Martin or Swern protocols followed by aqueous hypochlorite treatment affords the corresponding carboxylate which may be treated with cyanuric acid or a 2-fluoropyridinium reagent or thionyl chloride and KHF2 to give the acyl fluoride XVITI. Compound of formula Ie may then be obtained by treatment of XVLH with a fluorinating agent such as SF4 / HF or F3S-N(CH2CH2 ⁇ Me)2 followed by ester hydrolysis.
  • a fluorinating agent such as SF4 / HF or F3S-N(CH2CH2 ⁇ Me)2 followed by ester hydrolysis.
  • Scheme 11 depicts the preparation of compounds of Formula If and lg from the chiral indole Kb. Oxidation using DDQ in toluene and acetic acid followed by treatment with aqueous bicarbonate affords XK as a mixture of diastereomers. Coupling with chiral alcohol VIE under Mitsunobu conditions gives a separable mixture of isomers XXa and XXb. Final hydrolysis produces compounds of Formula If and lg.
  • ASSAYS FOR DETERMINING BIOLOGICAL ACTINITY Compounds of formula I can be tested using the following assays to determine their prostanoid antagonist or agonist activity in vitro and in vivo and their selectivity.
  • the prostaglandin receptor activities demonstrated are DP, EPj , , EP2, EP3, EP4, FP, IP, TP and CRTH2.
  • Stable expression of prostanoid receptors in the human embryonic kidney (HEK) 293(ebna) cell line Prostanoid receptor and CRTH2 cDNAs corresponding to full length coding sequences are subcloned into the appropriate sites of mammalian expression vectors and transfected into HEK 293(ebna) cells.
  • HEK 293(ebna) cells expressing the individual cDNAs are grown under selection and individual colonies are isolated after 2-3 weeks of growth using the cloning ring method and subsequently expanded into clonal cell lines.
  • Prostanoid receptor binding assays HEK 293(ebna) cells are maintained in culture, harvested and membranes are prepared by differential centrifugation, following lysis of the cells in the presence of protease inhibitors, for use in receptor binding assays.
  • Prostanoid receptor binding assays are performed in 10 mM MES/KOH (pH 6.0) (EPs, FP and TP) or 10 mM HEPES/KOH (pH 7.4) (DP, CRTH2 and IP), containing 1 mM EDTA, 10 mM divalent cation and the appropriate radioligand. The reaction is initiated by addition of membrane protein.
  • Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. Non-specific binding is determined in the presence of 1 ⁇ M of the corresponding non- radioactive prostanoid. Incubations are conducted for 60 min at room temperature or 30 °C and terminated by rapid filtration. Specific binding is calculated by subtracting non specific binding from total binding. The residual specific binding at each ligand concentration is calculated and expressed as a function of ligand concentration in order to construct sigmoidal concentration-response curves for determination of ligand affinity.
  • Prostanoid receptor agonist and antagonist assays Whole cell second messenger assays measuring stimulation (EP2, EP4, DP and IP in HEK 293(ebna) cells) or inhibition (EP3 in human erythroleukemia (HEL) cells) of intracellular cAMP accumulation or mobilization of intracellular calcium (EPi, FP and TP in HEK 293(ebna) cells stably transfected with apo-aequorin) are performed to determine whether receptor ligands are agonists or antagonists.
  • cAMP assays cells are harvested and resuspended in HBSS containing 25 mM HEPES, pH 7.4.
  • Incubations contain 100 ⁇ M RO-20174 (phosphodiesterase type IV inhibitor, available from Biomol) and, in the case of the EP3 inhibition assay only, 15 ⁇ M forskolin to stimulate cAMP production. Samples are incubated at 37°C for 10 min, the reaction is terminated and cAMP levels are then measured.
  • For calcium mobilization assays cells are charged with the co-factors reduced glutathione and coelenterazine, harvested and resuspended in Ham's F12 medium. Calcium mobilization is measured by monitoring luminescence provoked by calcium binding to the intracellular photoprotein aequorin. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations.
  • second messenger responses are expressed as a function of ligand concentration and both EC50 values and the maximum response as compared to a prostanoid standard are calculated.
  • the ability of a ligand to inhibit an agonist response is determined by Schild analysis and both Kg and slope values are calculated.
  • the maximal end of the tube is connected to a pneumotachograph and a flow and pressure signal is recorded on an oscilloscope linked to a computer for on-line calculation of NAR.
  • Nasal provocation is performed by the administration of an aerosolized solution (10 puffs/nostril). Changes in the NAR congestion are recorded prior to and for 60- 120 minutes post-challenge.
  • the animal is intubated with a cuffed endotracheal tube (4-6 mm I.D.) and anaesthesia is maintained via a continuous intravenous infusion of propofol (25-30 mg/kg/h).
  • Vital signs (heart rate, blood pressure, respiratory rate, body temperature) are monitored throughout the experiment.
  • Measurements of nasal congestion A measurement of the animal respiratory resistance is taken via a pneumotachograph connected to the endotracheal tube to ensure that it is normal.
  • An Ecovision accoustic rhinometer is used to evaluate nasal congestion. This technique gives a non-invasive 2D echogram of the inside of the nose.
  • nasal volume and the minimal cross-sectional area along the length of the nasal cavity are computed within 10 seconds by a laptop computer equipped with a custom software (Hood Laboratories, Mass, U.S.A.).
  • Nasal challenge is delivered directly to the animal's nasal cavity (50 ⁇ L volume).
  • the changes in nasal congestion are recorded prior to and for 60-120 minutes post-challenge. If nasal congestion occurs, it will translate into a reduction in the nasal volume.
  • Pulmonary Mechanics in Trained Conscious Squirrel Monkeys The test procedure involves placing trained squirrel monkeys in chairs in aerosol exposure chambers. For control purposes, pulmonary mechanics measurements of respiratory parameters are recorded for a period of about 30 minutes to establish each monkey's normal control values for that day.
  • compounds are dissolved or suspended in a 1% methocel solution (methylcellulose, 65HG, 400 cps) and given in a volume of 1 mL/kg body weight.
  • a DeVilbiss ultrasonic nebulizer is utilized. Pretreatment periods vary from 5 minutes to 4 hours before the monkeys are challenged with aerosol doses of either PGD2 or Ascaris suum antigen; 1:25 dilution.
  • each minute of data is calculated by computer as a percent change from control values for each respiratory parameter including airway resistance (RL) and dynamic compliance (C f jyn)-
  • the results for each test compound are subsequently obtained for a minimum period of 60 minutes post challenge which are then compared to previously obtained historical baseline control values for that monkey.
  • the overall values for 60 minutes post-challenge for each monkey are averaged separately and are used to calculate the overall percent inhibition of mediator or Ascaris antigen response by the test compound.
  • paired t-test is used. (References: McFarlane, C.S. et al, Prostaglandins, 28, 173-182 (1984) and McFarlane, C.S. et al., Agents Actions, 22, 63-68 (1987).)
  • Transpulmonary pressure the difference between tracheal pressure and pleural pressure, is measured with a differential pressure transducer (DP45; Validyne Corp., Northridge, CA).
  • DP45 differential pressure transducer
  • RL pulmonary resistance
  • the maximal end of the nasotrachel tube is connected to a pneumotachograph (Fleisch, Dyna Sciences, Blue Bell, PA).
  • Reference Example 7 (lR)-l-(4-bromophenyl)ethanol (froml-(4-bromophenyl)ethanone).
  • Reference Example 8 l-(4-chloro-2-fluorophenyl)ethanone To a solution 4-chloro-2-fluorobenzoic acid (leq) in CH 2 C1 2 (1.6 M) was added N,O-dimethylhydroxylamine hydrochloride (1.5 eq), EDCI (1.5 eq) and triethylamine (4 eq). The reaction mixture was stirred at rt for 16 hrs, concentrated and 0.5M aqueous citric acid was added. The mixture was extracted with 1:1 EtOAc:Et 2 O.
  • Step 1 2-(2-bromo-4-fluorophenyl)hvdrazinium chloride To a suspension of 2-bromo-4-fluoroaniline in concentrated HCl (1.5M) at -10 °C was slowly added a 10.0M aqueous solution of NaN0 2 (1.1 eq). The mixture was stirred at 0 °C for 2.5 hrs. A cold (-30 °C) solution of SnCl 2 (3.8M) in concentrated HCl was then slowly added while maintaining the internal temperature below 10 °C. The resulting mixture was stirred mechanically for 20 min at 0, then at room temperature for 1 hr. The thick slurry was filtered and the solid was air dried overnight. The solid was resuspended in cold HCl and filtered again. The dried material was suspended in Et 2 0, stirred for 10 min, filtered and air dried overnight to give the title compound as a beige solid.
  • Step 2 (+/-)-ethyl (8-bromo-6-fluoro-2,3.4.9-tetrahvdro-lH-carbazol-l-yl)acetate
  • ethyl (2- oxocyclohexyl)acetate (1 eq).
  • the mixture was stirred at reflux for 16 hrs, cooled and AcOH was removed by evaporation under reduced pressure.
  • the residue was diluted with EtOAc and washed with water and saturated aqueous NaHC0 3 .
  • the organic layer was dried over Na 2 S0 and concentrated.
  • Step 3 (+/-) -ethyl r6-fluoro-8-(methylsulfonyl)-2.3.4.9-tetrahydro-lH-carbazol-l-vn acetate
  • sodium methanesulphinate (3 eq)
  • copper iodide (3 eq)
  • N 2 was bubbled into the mixture for 5 min and the reaction was then stirred at 100 °C under N 2 atmosphere. After 12 hrs, more sodium methanesulphinate (2 eq) and copper iodide (2 eq) were added.
  • the mixture was stirred for a further 12hrs at 100 °C, cooled, diluted with EtOAc and IN ⁇ C1 was added to acidify the mixture.
  • the suspension was stirred for 30 min and filtered through celite.
  • the filtrate was washed with water, dried over Na 2 S0 4 and concentrated.
  • the residue was filtered through a pad of silica gel, eluting first with toluene to remove the non-polar impurities and then with a 2: 1 mixture of hexanes/EtOAc to elute the desired product.
  • the filtrate from the elution with the mixture of hexanes EtOAc was concentrated to give the title compound as a pale yellow solid.
  • Step 4 ethyl rdRV6-fluoro-8-(methylsulfonyl)-2.3.4.9-tetrahvdro-lH-carbazol-l-vn acetate
  • the racemic mixture from step 3 was resolved by preparative ⁇ PLC on a chiralpak AD preparative column eluted with a mixture of 15% iPrO ⁇ in hexane. The more polar enantiomer (longer retention time) was identified as the title compound based on the activity of the final product.
  • Step 5 ethyl r ⁇ R)-9-rriS -l-(4-chlorophenyl)ethvn-6-fluoro-8-fmethylsulfonyl -2.3.4.9- tetrahydro- lH-carbazol- 1 -yl! acetate
  • triphenylphosphine 1.5 eq
  • (1R)-1- (4-chlorophenyl)ethanol 1.5 eq, prepared following the general procedure described in Reference
  • Example 1 in T ⁇ F (0.175M) was added a solution of di-tert-butyl azodicarboxylate (2.1 M in T ⁇ F, 1.5 eq) over a 10 min period. The mixture was stirred at room temperature for 2hr and concentrated. The residue was purified by silica gel flash chromatography, eluting with 7% EtOAc in toluene to give the desired product (-90% pure) which was used as such for the next reaction.
  • Step 6 rdR g-rflS l- ⁇ -chloro henvDethyll-e-fluoro-S-fmethylsulfonvD ⁇ .S .g- tetrahydro-lH-carbazol-1-yllacetic acid and r(lS)-9-rdS)-l-f4- chlorophenyl)ethyll-6-fluoro-8-(methylsulfonyl)-2,3.4.9-tetrahydro-l ⁇ -carbazol- 1-yll acetic acid
  • 1 mixture of THF and methanol (0.1M) was added IN aqueous LiOH (3 eq).
  • Step 7 methyl f f lRV6-fluoro-8-(methylsulfonyl)-2.3.4.9-tetrahvdro-l ⁇ -carbazol-l - yll acetate
  • Example 1 The procedures described in Example 1 were followed using compound of Reference Example 10 and the approriate alcohols, to provide the compounds listed below following hydrolysis of their corresponding methyl esters:
  • Example 2 [(lR)-9-[(lS)-l-(3,4-dichlorophenyl)ethyl]-6-fluoro-8-(methylsulfonyl)-2,3,4,9- tetrahydro-lH-carbazol-l-yl]acetic acid starting from (li?)-l-(3,4-dichlorophenyl)ethanol.
  • Example 7 [(lR)-9-[(lS)-l-(4-chloro-2-fluorophenyl)ethyl]-6-fluoro-8-(methylsulfonyl)-2,3,4,9- tetrahydro-lH-carbazol-l-yl]acetic acid starting from (lR)-l-(4-chloro-2-fluorophenyl)ethanol.
  • MS (- APCI) m/z 480.1 (M-H) ⁇ [ ] D -250° in MeOH
  • Example 8 [(lR)-9-[(lS)-l-(4-bromophenyl)ethyl]-6-fluoro-8-(methylsulfonyl)-2,3,4,9-tetrahydro- lH-carbazol-1-yl] acetic acid starting from (lR)-l-(4-bromophenyl)ethanol.
  • MS (-APCI) m/z 506.1 (JM-
  • Step 1 methyl rdR)-6-fluoro-8-(methylsulfonyl)-4-oxo-2.3.4.9-tetrahydro-lH-carbazol- 1-vH acetate
  • DDQ methyl rdR-6-fluoro-8-(methylsulfonyl)-4-oxo-2.3.4.9-tetrahydro-lH-carbazol- 1-vH acetate
  • Step 2 (dRV6-fluoro-8-rmethylsulfonvD-4-oxo-9-(dS)-l-r4-ftrifluoromethvf)phenyl] ethyl)-2,3.4.9-tetrahydro-lH-carbazol-l-yl)acetic acid
  • Step 2 (dRV6-fluoro-8-rmethylsulfonvD-4-oxo-9-(dS)-l-r4-ftrifluoromethvf)phenyl] ethyl)-2,3.4.9-tetrahydro-lH-carbazol-l-yl)acetic acid
  • Step 1 methyl rdRVe-fluoro ⁇ -hvdroxy- ⁇ -CmethylsulfonvD- ⁇ .S .g-tetrahvdro-lH- carbazol- 1 -yll acetate
  • 1 eq methyl rdRVe-fluoro ⁇ -hvdroxy- ⁇ -CmethylsulfonvD- ⁇ .S .g-tetrahvdro-lH- carbazol- 1 -yll acetate
  • Step 2 rdi?.4R)-6-fluoro-4-hydroxy-8-fmethylsulfonylV9-ldS -l-r4-rtrifluoromethvD phenynethyll-2.3.4.9-tetrahydro-lH-carbazol-l-yl)acetic acid
  • triphenylphosphine 1.5 eq
  • (1R)-1- [4-(trifluoromethyl)phenyl]ethanol 1.5 eq
  • di-tert-butyl azodicarboxylate (1M in T ⁇ F, 1.5 eq).
  • the mixture was heated in microwave at 150°C under normal intensity for 5 min. cooled to rt and 1.5 eq of the alcohol, triphenylphosphine and di-tert-butyl azodicarboxylate were added. The mixture was heated in microwave for a further 5 min at 150°C at normal intensity and cooled to rt. The solvent was removed and the residue was purified by silica gel flash chromatography eluted with 10%- 60% EtOAc/hexanes to afford two isomers.
  • the less polar isomer was identified as methyl ((lR,4R)-6- fluoro-4-hydroxy-8-(methylsulfonyl)-9- ⁇ (lS)-l-[4-(trifluoromethyl)phenyl]ethyl ⁇ -2,3,4,9-tetrahydro-l ⁇ - carbazol-l-yl)acetate and the more polar isomer as methyl ((lR,4S)-6-fluoro-4-hydroxy-8- (methylsulfonyl)-9- ⁇ (lS)-l-[4-(trifluoromethyl)phenyl]ethyl ⁇ -2,3,4,9-tetrahydro-lH-carbazol-l- yl)acetate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des dérivés de tétrahydrocarbazole et de cyclopentanoindole substitués qui sont des antagonistes vis-à-vis du récepteur DP, et donc utiles pour le traitement des maladies dont la médiation est assurée par la prostaglandine D2 du type rhinite, asthme et congestion nasale.
EP04802298A 2003-12-15 2004-12-13 Derives de tetrahydrocarbazole et de cyclopentanoindole substitues Withdrawn EP1697322A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53029803P 2003-12-15 2003-12-15
PCT/CA2004/002123 WO2005056527A1 (fr) 2003-12-15 2004-12-13 Derives de tetrahydrocarbazole et de cyclopentanoindole substitues

Publications (2)

Publication Number Publication Date
EP1697322A1 true EP1697322A1 (fr) 2006-09-06
EP1697322A4 EP1697322A4 (fr) 2007-12-26

Family

ID=34676897

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04802298A Withdrawn EP1697322A4 (fr) 2003-12-15 2004-12-13 Derives de tetrahydrocarbazole et de cyclopentanoindole substitues

Country Status (7)

Country Link
US (1) US7019022B2 (fr)
EP (1) EP1697322A4 (fr)
JP (1) JP2007514005A (fr)
CN (1) CN1894213A (fr)
AU (1) AU2004296910A1 (fr)
CA (1) CA2548602A1 (fr)
WO (1) WO2005056527A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
BRPI0519280A2 (pt) 2004-12-27 2009-01-06 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
CA2598273A1 (fr) * 2005-02-17 2006-08-24 Merck & Co., Inc. Methode de traitement de l'atherosclerose, de dyslipidemies et de troubles lies
MX2007015905A (es) 2005-06-24 2008-03-06 Lilly Co Eli Derivados de tetrahidrocarbazol utiles como moduladores de receptor de androgeno (sarm).
WO2007010965A1 (fr) 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Dérivé d'azaindole ayant une activité antagoniste vis-à-vis du récepteur de la pgd2
EP1916245B1 (fr) 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Dérivé d'indole ayant une activité antagoniste vis-à-vis du récepteur de la pgd2
JP5147401B2 (ja) 2005-09-06 2013-02-20 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
CN101500996B (zh) 2006-08-07 2012-07-04 埃科特莱茵药品有限公司 (3-胺基-1,2,3,4-四氢-9h-咔唑-9-基)-乙酸衍生物
WO2008039882A1 (fr) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc Combinaison de niacine et d'un antagoniste du récepteur de prostaglandine d2
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
WO2008097535A2 (fr) * 2007-02-08 2008-08-14 Merck & Co., Inc. Procédé de traitement de l'athérosclérose, des dyslipidémies et d'états pathologiques apparentés
EP2134169A2 (fr) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Combinaison de metformine r-(+) lipoate et d'agents antihyperlipidémiques pour le traitement de l'hyperglycémie diabétique et de complications diabétiques
EP2245002A4 (fr) * 2008-02-01 2011-08-17 Amira Pharmaceuticals Inc Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
CA2713139C (fr) * 2008-02-01 2013-04-23 Amira Pharmaceuticals, Inc. Antagonistes aminoalkylbiphenyle disubstitues par n,n des recepteurs de la prostaglandine d2
WO2009102893A2 (fr) * 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. Composés diaryliques cycliques en tant qu'antagonistes de récepteurs de prostaglandine d2
JP2011513242A (ja) * 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
JP2011518130A (ja) * 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト
EP2119705A1 (fr) * 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Composé 3-aminocarbozole, composition pharmaceutique le contenant et son procédé de fabrication
PL2297100T3 (pl) 2008-05-16 2013-03-29 Lilly Co Eli Tetrahydrocyklopenta[B]indolowe modulatory receptora androgenowego
NZ589469A (en) * 2008-05-20 2012-08-31 Cerenis Therapeutics Holding S A Niacin and NSAID combination for reducing niacin-induced flushing
JP5531370B2 (ja) 2008-07-03 2014-06-25 パンミラ ファーマシューティカルズ，エルエルシー． プロスタグランジンｄ２受容体のアンタゴニスト
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (fr) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
WO2010057118A2 (fr) * 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
CA2768492A1 (fr) 2009-07-31 2011-02-03 Panmira Pharmaceuticals, Llc Compositions pharmaceutiques ophtalmiques d'antagonsites du recepteur dp2
CN102596902A (zh) * 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
MX2012007927A (es) 2010-01-06 2012-08-15 Panmira Pharmaceuticals Llc Antagonistas de dp2 y usos del mismo.
SI2558447T1 (sl) * 2010-03-22 2015-01-30 Actelion Pharmaceuticals Ltd. Derivati 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-karbazola in njihova uporaba kot modulatorji prostaglandinskega receptorja d2
BR112013026283A8 (pt) 2011-04-14 2018-01-30 Actelion Pharmaceuticals Ltd derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético e seu uso como moduladores do receptor d2 de prostaglandina
AR099767A1 (es) 2014-03-17 2016-08-17 Actelion Pharmaceuticals Ltd Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2
CN106103437A (zh) 2014-03-18 2016-11-09 埃科特莱茵药品有限公司 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途
CN106032383B (zh) * 2015-03-19 2019-08-13 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途
US10351560B2 (en) 2015-09-15 2019-07-16 Idorsia Pharmaceuticals Ltd Crystalline forms
CN112362781A (zh) * 2020-11-09 2021-02-12 河北诚信集团有限公司 一种甲基亚磺酸钠的含量测定方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0234708A1 (fr) * 1986-01-23 1987-09-02 Merck Frosst Canada Inc. Acides tétrahydrocarbazole 1-alcanoiques
EP0300676A2 (fr) * 1987-07-21 1989-01-25 Merck Frosst Canada Inc. Acides tétrahydrocarbazole-1-alcanoiques
CA1299577C (fr) * 1987-01-09 1992-04-28 John W. Gillard Acides tetrahydrocarbazole-1-alcanoiques
WO2002008186A2 (fr) * 2000-07-25 2002-01-31 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions contenant de tels composes et procedes de traitement
WO2003062200A2 (fr) * 2002-01-24 2003-07-31 Merck Frosst Canada & Co. Cycloalkanoindoles a substitution fluor, compositions contenant de tels composes, et procedes de traitement
WO2004103370A1 (fr) * 2003-05-15 2004-12-02 Merck & Co., Inc. Methode de traitement de l'atherosclerose, dyslipidemie et etats relatifs et compositions pharmaceutiques
WO2004103970A1 (fr) * 2003-05-20 2004-12-02 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl- cycloalkanoindoles substitues et leur utilisation en tant qu'antagonistes de prostaglandine d2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
EP1656141B1 (fr) 2003-08-07 2010-04-14 MERCK SHARP & DOHME LTD. Procede pour traiter la maladie d'alzheimer et des pathologies liees

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0234708A1 (fr) * 1986-01-23 1987-09-02 Merck Frosst Canada Inc. Acides tétrahydrocarbazole 1-alcanoiques
CA1299577C (fr) * 1987-01-09 1992-04-28 John W. Gillard Acides tetrahydrocarbazole-1-alcanoiques
EP0300676A2 (fr) * 1987-07-21 1989-01-25 Merck Frosst Canada Inc. Acides tétrahydrocarbazole-1-alcanoiques
WO2002008186A2 (fr) * 2000-07-25 2002-01-31 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions contenant de tels composes et procedes de traitement
WO2003062200A2 (fr) * 2002-01-24 2003-07-31 Merck Frosst Canada & Co. Cycloalkanoindoles a substitution fluor, compositions contenant de tels composes, et procedes de traitement
WO2004103370A1 (fr) * 2003-05-15 2004-12-02 Merck & Co., Inc. Methode de traitement de l'atherosclerose, dyslipidemie et etats relatifs et compositions pharmaceutiques
WO2004103970A1 (fr) * 2003-05-20 2004-12-02 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl- cycloalkanoindoles substitues et leur utilisation en tant qu'antagonistes de prostaglandine d2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005056527A1 *

Also Published As

Publication number Publication date
CA2548602A1 (fr) 2005-06-23
CN1894213A (zh) 2007-01-10
EP1697322A4 (fr) 2007-12-26
AU2004296910A1 (en) 2005-06-23
US7019022B2 (en) 2006-03-28
JP2007514005A (ja) 2007-05-31
US20050154044A1 (en) 2005-07-14
WO2005056527A1 (fr) 2005-06-23

Similar Documents

Publication Publication Date Title
US7019022B2 (en) Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
EP2045241B1 (fr) Cycloalkanoindoles substitués par un fluor et leur utilisation comme antagonistes du récepteur de prostaglandine D2
CA2416867C (fr) Cyclopentanoindoles, compositions contenant de tels composes et procedes de traitement
AU2003202343A1 (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists
AU2001277430A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
US20070054951A1 (en) Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
AU2007203428B2 (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060717

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060717

A4 Supplementary search report drawn up and despatched

Effective date: 20071123

17Q First examination report despatched

Effective date: 20080404

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081015